Global Spinal Muscular Atrophy Market Forecast 2026–2035 Presenting Long-Term Industry Expansion Insights

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Spinal Muscular Atrophy Market During 2026–2030?

The spinal muscular atrophy market has experienced rapid expansion in recent years. It is projected to increase from $4 billion in 2025 to $4.53 billion in 2026, at a compound annual growth rate (CAGR) of 13.2%. Historically, this growth has been attributed to the approval of breakthrough SMA therapies, increased genetic testing, heightened advocacy group awareness, substantial clinical trial investments, and funding dedicated to rare diseases.

The spinal muscular atrophy market is anticipated to experience substantial growth over the upcoming years, with projections indicating it will reach $7.34 billion by 2030, expanding at a compound annual growth rate (CAGR) of 12.9%. This projected growth is driven by the emergence of next-generation gene therapies, the increasing global adoption of screening methods, broadened access to treatment options, improvements in patient survival outcomes, and the ongoing development of drugs in the pipeline. Significant trends anticipated for this forecast period include earlier genetic diagnoses, the expansion of disease-modifying therapies, the implementation of newborn screening programs, the adoption of personalized treatment protocols, and a focus on long-term disease management.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20965&type=smp

What Drivers Are Expected To Influence The Spinal Muscular Atrophy Market During The Forecast Period?

An increase in the occurrence of rare genetic diseases is anticipated to fuel the expansion of the spinal muscular atrophy market in the coming period. These diseases are conditions resulting from gene mutations, impacting a small segment of the population and frequently leading to severe, chronic health issues. The growing incidence of rare genetic diseases is linked to advancements in diagnostic methods, greater public awareness, and improved access to genetic testing, all of which contribute to more identified and reported cases. Spinal muscular atrophy (SMA), itself a rare genetic disorder, serves as a prime example of the complexities and possibilities involved in comprehending inherited illnesses, underscoring the vital need for continued research into genetic conditions. As an illustration, a report released in July 2023 by the Office for National Statistics, a UK-based government department, indicated that SMN1 genetic testing has facilitated accurate epidemiological studies, showing that SMA affects 1 of 10,000 to 20,000 live births and that over 95% of patients with the condition are homozygous for the SMN1 deletion. Consequently, the increasing prevalence of rare genetic diseases will propel the growth of the spinal muscular atrophy market.

How Are The Various Segments Of The Spinal Muscular Atrophy Market Categorized?

The spinal muscular atrophy market covered in this report is segmented –

1) By Type: Type 1 (Severe), Type 2 (Intermediate), Type 3 (Mild), Type 4 (Adult)

2) By Age: Pediatric, Adults

3) By Treatment: Drug Therapy, Gene Therapy

4) By End User: Hospital pharmacy, Online pharmacy, Retail pharmacy

Subsegments:

1) By Type 1 (Severe): Infantile-Onset SMA, Severe Progressive SMA

2) By Type 2 (Intermediate): Early-Onset SMA, Non-progressive SMA

3) By Type 3 (Mild): Juvenile-Onset SMA, Mild Progressive SMA

4) By Type 4 (Adult): Adult-Onset SMA, Late-Onset SMA

How Are Trends Transforming The Spinal Muscular Atrophy Market Landscape?

Prominent companies active in the spinal muscular atrophy market are creating novel products, like dry syrup, to enhance patient compliance with medication and simplify its administration for children and other patients who have trouble swallowing. This powdered medicine is reconstituted with water prior to use and is frequently prescribed for children and individuals who struggle to ingest tablets or capsules. For example, in September 2024, Chugai Pharmaceutical Co., Ltd., a pharmaceutical firm based in Japan, disclosed regulatory clearance from Japan’s Ministry of Health, Labour and Welfare for a broadened indication of its medicine, Evrysdi (risdiplam). The approval permits its application in pre-symptomatic spinal muscular atrophy (SMA) and extends the dosing regimen to infants younger than two months old. This significant development is vital because it facilitates the start of treatment prior to symptom manifestation, potentially improving therapeutic results for affected infants. The decision was underpinned by data from the RAINBOWFISH study, which evaluated Evrysdi’s safety and effectiveness in infants diagnosed with SMA who had not yet presented symptoms. Results indicated that treated infants reached developmental milestones, including unsupported sitting and enhanced motor skills, by 12 months, highlighting the medicine’s capacity to alter the disease’s advancement with early intervention.

Which Major Firms Influence Developments In The Spinal Muscular Atrophy Market?

Major companies operating in the spinal muscular atrophy market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Bayer AG, Novartis AG, Biogen Inc., Chugai Pharmaceutical Co. Ltd., Genentech Inc., PTC Therapeutics Inc., Ionis Pharmaceuticals Inc., RegenXBio Inc., Cytokinetics Inc., AveXis Inc., Scholar Rock Inc., Genethon, CANbridge Pharmaceuticals Inc., NMD Pharma A/S, Hanugen Therapeutics Inc., Beijing Jinlan Gene Technology Co. Ltd, Sarepta Therapeutics, Amicus Therapeutics, Audentes Therapeutics, Solid Biosciences

Read the full spinal muscular atrophy market report here:

https://www.thebusinessresearchcompany.com/report/spinal-muscular-atrophy-global-market-report

Which Region Is Forecast To Lead The Spinal Muscular Atrophy Market In Terms Of Market Size?

North America was the largest region in the spinal muscular atrophy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the spinal muscular atrophy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Spinal Muscular Atrophy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20965&type=smp

Browse Through More Reports Similar to the Global Spinal Muscular Atrophy Market 2026, By The Business Research Company

Spine Biologics Global Market Report

https://www.thebusinessresearchcompany.com/report/spine-biologics-global-market-report

Muscle Wasting Disorders Global Market Report

https://www.thebusinessresearchcompany.com/report/muscle-wasting-disorders-global-market-report

Duchenne Muscular Dystrophy Dmd Therapeutics Global Market Report

https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-dmd-therapeutics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795